Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895322 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1EPHX2DPP4NR1H2 | |
| SCHEMBL2895324 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1EPHX2DPP4NR1H2 | |
| SCHEMBL30267115 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1EPHX2DPP4NR1H2 | |
| SCHEMBL172785 | 0.86 | TDP1 (0.60) | TDP1SIGMAR1EPHX2DPP4NR1H2 | |
| SCHEMBL944228 | 0.86 | TDP1 (0.60) | TDP1SIGMAR1EPHX2DPP4NR1H2 | |
| SCHEMBL23170436 | 0.84 | TDP1 (0.58) | TDP1SIGMAR1EPHX2DPP4NR1H2 | |
| SCHEMBL13028980 | 0.83 | TDP1 (0.57) | TDP1SIGMAR1EPHX2DPP4NR1H2 | |
| SCHEMBL172970 | 0.81 | SIGMAR1 (0.61) | TDP1SIGMAR1EPHX2DPP4NR1H2 | |
| SCHEMBL24105937 | 0.81 | TDP1 (0.56) | TDP1SIGMAR1EPHX2DPP4NR1H2 | |
| SCHEMBL4872520 | 0.80 | SIGMAR1 (0.60) | TDP1SIGMAR1EPHX2DPP4NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | TDP1 2130/4885SIGMAR1 1602/4885EPHX2 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.